Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Goatman KA, Fleming AD, Philip S, Williams GJ, Olson JA, Sharp PF. Detection of new vessels on the optic disc using retinal photographs. IEEE T Med Imaging. 2011 Apr 1;30(4):972-9. doi: 10.1109/TMI.2010.2099236.
Fleming AD, Philip S, Goatman KA, Olson JA, Sharp PF. Automated microaneurysm detection using local contrast normalization and local vessel detection. IEEE T Med Imaging. 2006 Sep 1;25(9):1223-32. doi: 10.1109/tmi.2006.879953
Norton EC, Zarkin GA, Calingaert B, Bradley CJ. The effect of maternal substance abuse on the cost of neonatal care. Inquiry. 1996;33(3):247-57.